Evidence for Peroxisome Proliferator-Activated Receptor (PPAR)α-Independent Peroxisome Proliferation: Effects of PPARγ/δ-Specific Agonists in PPARα-Null Mice
- 1 September 2000
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 58 (3) , 470-476
- https://doi.org/10.1124/mol.58.3.470
Abstract
Peroxisome proliferators are a diverse group of compounds that cause hepatic hypertrophy and hyperplasia, increase peroxisome number, and on chronic high-dose administration, lead to rodent liver tumorigenesis. Various lines of evidence have led to the conclusion that these agents induce their pleiotropic effects exclusively via agonism of peroxisome proliferator-activated receptor (PPAR)α, a member of the steroid receptor superfamily involved in the regulation of fatty acid metabolism. Recently, agonists of two other members of this receptor family have been identified. PPARγ is predominantly expressed in adipocytes where it mediates differentiation; PPARδ is a widely expressed orphan receptor with yet unresolved physiologic functions. In the course of characterizing newer PPAR ligands, we noted that highly selective PPARγ agonists or dual PPARγ/PPARδ agonists, lacking apparent murine PPARα agonist activity, cause peroxisome proliferation in CD-1 mice. We therefore made use of PPARα knockout mice to investigate whether these effects resulted from agonism of PPARα by these agents at very high dose levels or whether PPARγ (or PPARδ) agonism alone can result in peroxisome proliferation. We report here that several parameters linked to the hepatic peroxisome proliferation response in mice that were seen with these agents resulted from PPARα-independent effects.Keywords
This publication has 24 references indexed in Scilit:
- Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese miceJournal of Lipid Research, 1999
- Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological EffectsJournal of Biological Chemistry, 1999
- Mechanism of Action of the Nongenotoxic Peroxisome Proliferators: Role of the Peroxisome Proliferator-Activated ReceptorJNCI Journal of the National Cancer Institute, 1998
- Peroxisome Proliferator-activated Receptor α-Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and SteatosisJournal of Biological Chemistry, 1998
- Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceEndocrinology, 1996
- Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2Biochemical and Biophysical Research Communications, 1996
- Differential activation of adipogenesis by multiple PPAR isoforms.Genes & Development, 1996
- Mechanisms of regulation of liver fatty acid-binding proteinMolecular and Cellular Biochemistry, 1993
- Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor.Proceedings of the National Academy of Sciences, 1993
- Biogenesis of peroxisomes: immunocytochemical investigation of peroxisomal membrane proteins in proliferating rat liver peroxisomes and in catalase-negative membrane loops.The Journal of cell biology, 1989